pioglitazone has been researched along with Chronic Illness in 16 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 9.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 7.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "Pioglitazone treatment reduced the severity of ulceration, repressed levels of TNF-alpha, IL-1beta and nuclear p65 subunit as well as increased the abundance of PPAR-gamma in gastric mucosa." | 5.35 | Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. ( Lahiri, S; Palit, G; Sen, T, 2009) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 5.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 3.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "The present results suggest that pioglitazone improves not only insulin resistance, but also the dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in the hyperinsulinaemic state." | 3.74 | Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. ( Egawa, T; Hanafusa, N; Kawasaki, H; Mio, M; Takatori, S; Yabumae, N; Zamami, Y, 2008) |
| " Therefore, we examined the effect of pioglitazone, a PPARgamma agonist, on chronic left ventricular remodeling after experimental myocardial infarction (MI) in mice." | 3.72 | Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. ( Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Galuppo, P; Hu, K; Schmidt, I; Strotmann, J; Widder, J; Witzel, CC, 2004) |
| "Pioglitazone treated TBI rats performed significantly better in the RAM test than untreated TBI rats, and similarly to control animals." | 1.51 | Pioglitazone improves working memory performance when administered in chronic TBI. ( Anwar, FN; Correll, EA; Lowery, AC; McCullumsmith, RE; McGuire, JL; Ngwenya, LB; Rhame, K, 2019) |
| "Pioglitazone was administered intragastrically once per day for 3 weeks at different doses." | 1.43 | The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. ( Fan, Y; Peng, C; Wu, X; Xie, X; Yan, S; You, Z; Zhang, J; Zhao, Q, 2016) |
| "Pioglitazone treatment reduced the severity of ulceration, repressed levels of TNF-alpha, IL-1beta and nuclear p65 subunit as well as increased the abundance of PPAR-gamma in gastric mucosa." | 1.35 | Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. ( Lahiri, S; Palit, G; Sen, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, SY | 1 |
| Huang, CC | 1 |
| Huang, SF | 1 |
| Liao, TL | 1 |
| Kuo, NR | 1 |
| Yang, YY | 1 |
| Li, TH | 1 |
| Liu, CW | 1 |
| Hou, MC | 1 |
| Lin, HC | 1 |
| Colca, JR | 1 |
| Scherer, PE | 1 |
| McGuire, JL | 1 |
| Correll, EA | 1 |
| Lowery, AC | 1 |
| Rhame, K | 1 |
| Anwar, FN | 1 |
| McCullumsmith, RE | 1 |
| Ngwenya, LB | 1 |
| Okada, K | 1 |
| Hosooka, T | 1 |
| Shinohara, M | 1 |
| Ogawa, W | 1 |
| Zhang, X | 1 |
| Li, N | 1 |
| Lu, L | 1 |
| Lin, Q | 1 |
| Li, L | 1 |
| Dong, P | 1 |
| Yang, B | 1 |
| Li, D | 1 |
| Fei, J | 1 |
| Iranpour, N | 1 |
| Zandifar, A | 1 |
| Farokhnia, M | 1 |
| Goguol, A | 1 |
| Yekehtaz, H | 1 |
| Khodaie-Ardakani, MR | 1 |
| Salehi, B | 1 |
| Esalatmanesh, S | 1 |
| Zeionoddini, A | 1 |
| Mohammadinejad, P | 1 |
| Zeinoddini, A | 1 |
| Akhondzadeh, S | 1 |
| Zhao, Q | 1 |
| Wu, X | 1 |
| Yan, S | 1 |
| Xie, X | 1 |
| Fan, Y | 1 |
| Zhang, J | 1 |
| Peng, C | 1 |
| You, Z | 1 |
| Lahiri, S | 1 |
| Sen, T | 1 |
| Palit, G | 1 |
| Takemoto, M | 1 |
| Yokote, K | 1 |
| Konrat, C | 1 |
| Boutron, I | 1 |
| Trinquart, L | 1 |
| Auleley, GR | 1 |
| Ricordeau, P | 1 |
| Ravaud, P | 1 |
| Pan, Y | 1 |
| Hong, Y | 1 |
| Zhang, QY | 1 |
| Kong, LD | 1 |
| Hassler, D | 1 |
| Frantz, S | 1 |
| Hu, K | 1 |
| Widder, J | 1 |
| Bayer, B | 1 |
| Witzel, CC | 1 |
| Schmidt, I | 1 |
| Galuppo, P | 1 |
| Strotmann, J | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Robertshaw, H | 1 |
| Friedmann, PS | 1 |
| Takatori, S | 1 |
| Zamami, Y | 1 |
| Yabumae, N | 1 |
| Hanafusa, N | 1 |
| Mio, M | 1 |
| Egawa, T | 1 |
| Kawasaki, H | 1 |
| Karagiannis, E | 1 |
| Pfützner, A | 1 |
| Forst, T | 1 |
| Lübben, G | 1 |
| Roth, W | 1 |
| Grabellus, M | 1 |
| Flannery, M | 1 |
| Schöndorf, T | 1 |
2 reviews available for pioglitazone and Chronic Illness
| Article | Year |
|---|---|
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
[Prevention, treatment and management of inflammation in atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Biomarkers; C-Reactive Protein; Chronic D | 2011 |
1 trial available for pioglitazone and Chronic Illness
| Article | Year |
|---|---|
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2016 |
13 other studies available for pioglitazone and Chronic Illness
| Article | Year |
|---|---|
Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats.
Topics: Acute Disease; Alanine Transaminase; Animals; Ascites; Bile Ducts; Bilirubin; Blood Vessels; Chronic | 2021 |
Pioglitazone improves working memory performance when administered in chronic TBI.
Topics: Animals; Brain; Brain Injuries, Traumatic; Chronic Disease; Male; Maze Learning; Memory, Short-Term; | 2019 |
Modulation of lipid mediator profile may contribute to amelioration of chronic inflammation in adipose tissue of obese mice by pioglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cytokines; Diabetes Mellitus, Ty | 2018 |
Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ.
Topics: Animals; Chronic Disease; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Hypoglycemic A | 2019 |
The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.
Topics: Animals; Antidepressive Agents; Body Weight; Cell Line, Transformed; Chronic Disease; Cytokines; Dis | 2016 |
Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Topics: Animals; Anti-Ulcer Agents; Chronic Disease; Dose-Response Relationship, Drug; Female; Gastric Mucos | 2009 |
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France | 2012 |
Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system.
Topics: Anhedonia; Animals; Antidepressive Agents; Arcuate Nucleus of Hypothalamus; Chronic Disease; Cortico | 2013 |
[What is to be made of the therapy of borreliosis with cholestyramine and pioglitazone?].
Topics: Anti-Bacterial Agents; Cholestyramine Resin; Chronic Disease; Humans; Lyme Disease; Neurotoxins; Pio | 2003 |
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Chronic Disease; Collagen; Coronary Vessels; Cytokines; | 2004 |
Pioglitazone: a promising therapy for psoriasis.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Humans; Male; Middle Aged; Pilot Projects; Piog | 2005 |
Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Chronic Disease; Disea | 2008 |
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
Topics: Aged; Blood Pressure; Body Mass Index; Chronic Disease; Diabetes Mellitus, Type 2; Drug Monitoring; | 2008 |